Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma

Multiple Myeloma (MM)

Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

J Clin Apher.

Moreb JS, Byrne M, Shugarman I, Zou F, Xiong S, May WS, Norkin M, Hiemenz J, Brown R, Cogle C, Wingard JR, Hsu JW

doi: 10.1002/jca.21556.

Multiple Myeloma (MM)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Leukemia.

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H

doi: 10.1038/leu.2017.122.

Multiple Myeloma (MM)

Analysis of Clinical Factors and Outcomes Associated with Non-Utilization of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant Eligible Patients with Multiple Myeloma

Biol Blood Marrow Transplant.

Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, Rajkumar SV, Kyle RA, Hogan W, Kumar SK

doi: 10.1016/j.bbmt.2018.04.007.

Multiple Myeloma (MM)

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

J Clin Oncol.

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M

doi: 10.1200/

Multiple Myeloma (MM)

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation

Bone Marrow Transplant.

Pandit A, Leblebjian H, Hammond SP, Laubach JP, Richardson PG, Baden LR, Marty FM, Issa NC

doi: 10.1038/s41409-018-0112-x.

Multiple Myeloma (MM)

Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation

Leuk Lymphoma.

Mürner CM, Stenner-Liewen F, Seifert B, Mueller NJ, Schmidt A, Renner C, Schanz U, Knuth A, Manz MG, Scharl M, Gerber B, Samaras P

doi: 10.1080/

Multiple Myeloma (MM)

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

Lancet Haematol.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM

doi: 10.1016/S2352-

Multiple Myeloma (MM)

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Lancet Haematol.

Cook G, Ashcroft AJ, Cairns DA, Williams CD, Brown JM, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H, Bird JM, Pratt G, Chown S, Heartin E, O'Connor S, Drayson MT, Hockaday A, Morris TC; National Cancer Research Institute Haemato-oncology Clinical Studies Group

doi: 10.1016/

RECOMMENDED

Multiple Myeloma (MM)

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

★ 2 Recommended by Alexander Meisel, Faculty Member

J Clin Oncol.

Dimopoulos MA, Špička I, Quach H, Oriol A, Hájek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S, TOURMALINE-MM4 study group.

doi: 10.1200/JCO.20.02060.Visit the full text of the original publication at ascopubs.org

Related content

Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Analysis of Clinical Factors and Outcomes Associated with Non-Utilization of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant Eligible Patients with Multiple Myeloma

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation

Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial